182 related articles for article (PubMed ID: 21599533)
1. Pharmacokinetics and tolerability of BAY41-6551 in subjects with chronic kidney disease.
Stass H; Corkery K; Gribben D; Eldon MA
J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):191-9. PubMed ID: 21599533
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.
Luyt CE; Eldon MA; Stass H; Gribben D; Corkery K; Chastre J
J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):183-90. PubMed ID: 21361783
[TBL] [Abstract][Full Text] [Related]
3. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia.
Niederman MS; Chastre J; Corkery K; Fink JB; Luyt CE; García MS
Intensive Care Med; 2012 Feb; 38(2):263-71. PubMed ID: 22147112
[TBL] [Abstract][Full Text] [Related]
4. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
6. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
Sobue S; Tan K; Layton G; Leclerc V; Weil A
Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
[TBL] [Abstract][Full Text] [Related]
8. Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system.
Ghazi IM; Grupper M; Nicolau DP
Ann Clin Microbiol Antimicrob; 2017 Jan; 16(1):2. PubMed ID: 28095918
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
10. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.
Courtney R; Sansone A; Smith W; Marbury T; Statkevich P; Martinho M; Laughlin M; Swan S
J Clin Pharmacol; 2005 Feb; 45(2):185-92. PubMed ID: 15647411
[TBL] [Abstract][Full Text] [Related]
11. [In the search for effective and safe dose of amikacin in patients with chronic kidney disease].
Gomółka M; Szamotulska K; Rymarz A; Brodowska-Kania D; Dubchak I; Piechota W; Jurkiewicz D; Niemczyk S
Pol Merkur Lekarski; 2014 Apr; 36(214):240-4. PubMed ID: 24868895
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
[TBL] [Abstract][Full Text] [Related]
13. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of repaglinide in subjects with renal impairment.
Marbury TC; Ruckle JL; Hatorp V; Andersen MP; Nielsen KK; Huang WC; Strange P
Clin Pharmacol Ther; 2000 Jan; 67(1):7-15. PubMed ID: 10668848
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects.
Ehrmann S; Mercier E; Vecellio L; Ternant D; Paintaud G; Dequin PF
Intensive Care Med; 2008 Apr; 34(4):755-62. PubMed ID: 18046534
[TBL] [Abstract][Full Text] [Related]
17. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T
Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441
[TBL] [Abstract][Full Text] [Related]
18. Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients.
El-Assal MI; Helmy SA
Biopharm Drug Dispos; 2014 Oct; 35(7):405-16. PubMed ID: 25044219
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
Zhou XJ; Swan S; Smith WB; Marbury TC; Dubuc-Patrick G; Chao GC; Brown NA
Antimicrob Agents Chemother; 2007 Dec; 51(12):4231-5. PubMed ID: 17875994
[TBL] [Abstract][Full Text] [Related]
20. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity.
Gálvez R; Luengo C; Cornejo R; Kosche J; Romero C; Tobar E; Illanes V; Llanos O; Castro J
Int J Antimicrob Agents; 2011 Aug; 38(2):146-51. PubMed ID: 21612894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
